HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The role of gemcitabine in the treatment of malignant mesothelioma.

Abstract
Gemcitabine is broadly active in a variety of solid tumors, including malignant mesothelioma. In vitro, gemcitabine demonstrates activity against mesothelioma cell lines. The role of single-agent gemcitabine in patients with mesothelioma is unclear, since three phase II trials treated a total of 60 patients and achieved response rates of 0%, 7%, and 31%. The combination of gemcitabine and cisplatin is synergistic against mesothelioma cell lines in vitro. Gemcitabine in combination with cisplatin or carboplatin shows definite activity in phase II trials. The trial by Byrne and colleagues that demonstrated a response rate of 48% established the combination of gemcitabine plus cisplatin as a standard therapy for this disease in the United States. Subsequent multicenter trials have achieved lower response rates of 26% and 16% for this combination. Gemcitabine plus carboplatin also has activity. Future roles for gemcitabine in malignant mesothelioma patients include incorporating a gemcitabine/platinum regimen for neoadjuvant or adjuvant therapy, combining it with other cytotoxic chemotherapy agents such as pemetrexed or vinorelbine, or adding novel cytostatic agents such as the vascular endothelial growth factor (VEGF) inhibitor, bevacizumab, to the gemcitabine and platinating agent combination.
AuthorsHedy Lee Kindler, Jan P van Meerbeeck
JournalSeminars in oncology (Semin Oncol) Vol. 29 Issue 1 Pg. 70-6 (Feb 2002) ISSN: 0093-7754 [Print] United States
PMID11836671 (Publication Type: Journal Article, Review)
CopyrightCopyright 2002 by W.B. Saunders Company.
Chemical References
  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Carboplatin
  • Cisplatin
  • Gemcitabine
Topics
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carboplatin (administration & dosage)
  • Cisplatin (administration & dosage)
  • Clinical Trials as Topic
  • Deoxycytidine (administration & dosage, analogs & derivatives, therapeutic use)
  • Humans
  • Mesothelioma (drug therapy)
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: